A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2017
At a glance
- Drugs AZD 9150 (Primary) ; Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Sponsors MedImmune
- 07 Jun 2017 Biomarkers information updated
- 25 Oct 2016 Planned number of patients changed from 186 to 180.
- 25 Oct 2016 Planned End Date changed from 1 Jun 2021 to 1 Jul 2021.